A01K 2217/052
Inducing gain of function
Official title: inducing gain of function
A01K2217/052 (Inducing gain of function) appears on 531 US grants and 1,070 published applications in this corpus.
Search patents in A01K- Granted patents
- 531
- Published applications
- 1,070
- Assignees
- 475
- Inventors
- 1,766
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 0 |
| 2002 | 3 | 3 |
| 2003 | 1 | 7 |
| 2004 | 0 | 5 |
| 2005 | 2 | 10 |
| 2006 | 2 | 8 |
| 2007 | 3 | 6 |
| 2008 | 3 | 20 |
| 2009 | 10 | 23 |
| 2010 | 5 | 56 |
| 2011 | 10 | 49 |
| 2012 | 22 | 46 |
| 2013 | 26 | 59 |
| 2014 | 17 | 59 |
| 2015 | 51 | 68 |
| 2016 | 42 | 87 |
| 2017 | 46 | 87 |
| 2018 | 41 | 62 |
| 2019 | 36 | 64 |
| 2020 | 41 | 60 |
| 2021 | 31 | 49 |
| 2022 | 34 | 55 |
| 2023 | 27 | 49 |
| 2024 | 23 | 56 |
| 2025 | 29 | 51 |
| 2026 | 17 | 31 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Genetically modified non-human animal with human or chimeric TFR122 Sep 2026US 12,740,550 B2Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Multi-transgenic pig for Xenotransplantation25 Aug 2026US 12,714,077 B2Revivicor, Inc.
- Pharmaceutical composition for treating degenerative brain disease, including glycine transporter as active ingredient18 Aug 2026US 12,708,657 B2Amyloid Solution Inc.
- Combined light and electrical stimulation of light-sensitive neural tissue18 Aug 2026US 12,708,762 B2The Bionics Institute of Australia
- Tissue selective transgene expression28 Jul 2026US 12,692,516 B2Encoded Therapeutics, Inc.
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Mouse model with humanized telomere1 Oct 2026US 2026/0293864 A1Washington State Univesity
- Single-sex chicken with toxin-antitoxin system1 Oct 2026US 2026/0293865 A1New York University
- Use of inhibitors of adam12 as adjuvants in tumor therapies24 Sep 2026US 2026/0286009 A1Institut National de la Sante et de la Recherche Medicale
- Woolly mammoth specific gene variants and compositions comprising same17 Sep 2026US 2026/0274907 A1Colossal Biosciences Inc.
Most cited
By later US patents
- Methods of treatment using anti-ErbB antibody-maytansinoid conjugates152US 7,097,840 B2Genentech, Inc. · 2006
- Transgenic animals bearing human Igλ light chain genes134US 7,435,871 B2Amgen Fremont Inc. · 2008
- Compositions and methods for the treatment and diagnosis of immune disorders111US 6,562,343 B1Millennium Pharmaceuticals, Inc. · 2003
- Compositions and methods for the treatment and diagnosis of immune disorders106US 6,414,117 B1Millennium Pharmaceuticals, Inc. · 2002
- Methods of treatment using anti-ErbB antibody-maytansinoid conjugates70US 7,575,748 B1Genentech, Inc. · 2009